Skip to content

Released Feb 4, 2022, before the open

10-Q filed Feb 4, 2022, 35 days after period end · 0001764013-22-000031

Q3 2022 · 10-Q
Revenue—
Net Income-$41.39Mno prior Q3 2021 on fileN/M vs Q2 2022
EPS Diluted-$0.36no prior Q3 2021 on fileN/M vs Q2 2022
Operating Cash Flowderived-$31,895,000—
Free Cash Flowderived-$31,969,000—

What the release said

The release

Same quarter

MetricQ3 2022Q3 2018
Net Income-$41.39M-$8.85M
EPS Diluted-$0.36-$0.24

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Immunovant, Inc. · CIK 1764013 · Engraved from SEC EDGAR